REPLIGEN CORP acquired Novozymes Biopharma (Novozymes Biopharma Sweden AB) for ~$22.7 million (EUR 17 million) cash + up to EUR 4 million (~$5.6M) milestones, a transaction completed in December 2011, structured as all cash plus contingent milestones.
Novozymes Biopharma (Novozymes Biopharma Sweden AB) operates in Proteins / bioprocessing consumables, is based in Lund, Sweden. Acquisition of the bioprocessing business of Novozymes Biopharma Sweden AB, a supplier of cell-culture growth factors and other products used in the manufacture of biologic drugs. Repligen called it a transformative deal that elevated the company to a world-leading supplier of products for manufacturing biologic drugs and accelerated its path to sustainable profitability.
Repligen described the deal as positioning it 'as a leading producer of high value, consumable products that will directly benefit from the long-term growth of the biologics market,' delivering on its strategic objective to transition into a commercially focused company.
Established consumable-product revenue with exposure to long-term biologics manufacturing growth. Repligen bioprocessing operations (Sweden)
This acquisition positions Repligen as a leading producer of high value, consumable products that will directly benefit from the long-term growth of the biologics market. Earlier this year we announced our strategic objective to transition into a commercially focused company, and the acquisition of the Novozymes business will deliver on that goal.Walter C. Herlihy, President and CEO, Repligen Corporation
Advisory firms were not disclosed for this transaction.